Fig. 1 · Structure

Documents & Downloads

Cisatracurium besylate

Cat. No. A11834 CAS 96946-42-8

neuromuscular blocking agent

Cisatracurium besylate (51W89) is a nondepolarizing neuromuscular blocking agent, antagonizing the action of acetylcholine by inhibiting neuromuscular transmission.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Cisatracurium besylate Research Summary

This section summarizes 2 in vitro studies of Cisatracurium besylate from 1 published reference. In vitro models include HUVECs.

Cisatracurium besylate In Vitro Studies

Cisatracurium besylate increased the number of autophagic structures in a concentration-dependent manner in HeLa cells stably transfected with markers for autophagosome-like structures and mitochondria. In HUVECs, incubation with Cisatracurium besylate increased autolysosome numbers in a concentration-dependent manner. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Cisatracurium increases autophagic structures in HeLa cells

Cell-based study · HeLa cells stably transfected with GFP-LC3 (marks autophagosome-like structures) and MitoDsred (marks mitochondria) [1]

HeLa cells stably transfected with markers for autophagosome-like structures and mitochondria were incubated with cisatracurium. The number of autophagic structures increased in a concentration-dependent manner.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
LC3 green fluorescent puncta in each cell were countedReported result With increase in drug concentration, the number of LC3-positive autophagic structures increased in a concentration-dependent manner.[1]

Literature-Reported Treatment Conditions

Treatment concentration
2.5 µM, 5 µM, 10 µM, 25 µM, 50 µM, or 100 µM
Exposure duration
for 12 h
Method
incubated with cisatracurium
Reported limits
Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Cisatracurium besylate; Compound label in the paper: Cisatracurium

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

2. Results > 2.1. Cisatracurium Besylate Promotes Mitochondrial Breakage, Mitochondrial Protein Degradation and Colocalization of Mitochondria and Autophagosomes (S6, S7, S9); Figure 1 legend (S130)

LC3 green fluorescent puncta in each cell were counted: LC3 green fluorescent puncta in each cell were counted; comparator: 0 µM — 2. Results > 2.1. Cisatracurium Besylate Promotes Mitochondrial Breakage, Mitochondrial Protein Degradation and Colocalization of Mitochondria and Autophagosomes (S7, S9)

Cisatracurium increases autolysosome numbers in HUVECs

Cell-based study · HUVECs [1]

HUVECs were incubated with cisatracurium. Autolysosome numbers increased in a concentration-dependent manner.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
The number of the autolysomesReported result The number of the autolysomes increases in a concentration dependent manner.[1]

Literature-Reported Treatment Conditions

Treatment concentration
5 µM, 25 µM, or 100 µM
Exposure duration
for 12 h
Method
incubated with cisatracurium
Reported limits
Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Cisatracurium besylate; Compound label in the paper: Cisatracurium

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

2. Results > 2.2. Cisatracurium Besylate Promotes Autolysosome Formation (S43); Figure 2 legend (S144, S147)

The number of the autolysomes: The number of the autolysomes; comparator: control group — Figure 2 legend (S147)

Specifications

Manufacturer Adooq Bioscience
CAS Number 96946-42-8
Applications neuromuscular blocking agent
Formula C65H82N2O18S2
Molecular Weight 1243.48
Synonyms 51W89
SMILES
O=C(OCCCCCOC(CC[N@+]1(C)[C@H](CC2=CC=C(OC)C(OC)=C2)C3=C(C=C(OC)C(OC)=C3)CC1)=O)CC[N@+]4(C)[C@H](CC5=CC=C(OC)C(OC)=C5)C6=C(C=C(OC)C(OC)=C6)CC4.O=S(C7=CC=CC=C7)([O-])=O.O=S(C8=CC=CC=C8)([O-])=O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 212 mg/mL (170.49 mM)
Water 40 mg/mL (32.16 mM)
Ethanol 212 mg/mL (170.49 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Cisatracurium besylate Research References

  1. [1] Zhuang H, Tian W, Li W, et al. Autophagic Cell Death and Apoptosis Jointly Mediate Cisatracurium Besylate-Induced Cell Injury. Int J Mol Sci (2016). PMID: 27058536 DOI: 10.3390/ijms17040515 Source material

Added to your cart

View Cart Checkout
Loading...